Pacira Pharmaceuticals Inc (PCRX)
Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) is a common stock listing tied to Pacira BioSciences, Inc., a healthcare company focused on non-opioid pain management and regenerative health solutions. The company develops, manufactures, markets, distributes, and sells its products to healthcare practitioners in the United States. Its portfolio includes EXPAREL, a bupivacaine liposome injectable suspension used for postsurgical pain control; ZILRETTA, an extended-release injectable suspension for osteoarthritis-related knee pain; and the iovera system, a handheld cryoanalgesia device designed to interrupt pain signals by applying controlled cold to targeted nerves. Pacira is also advancing PCRX-201, a gene therapy vector platform intended for local delivery of genetic medicines, and it has a development and commercialization agreement related to NOCITA for veterinary use. The company was incorporated in 2006 and is headquartered in Brisbane, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PCRX
|
$34.83
|
38.6% Upside
|
Undervalued
|
$29.67
|
18.0% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 4, 2026
|
192.3x
|
1.5x
|
1.3x
|
997.5 M
|
1.174 B
|
29.2%
|
85.7%
|
2.3
|
—
|
2,582.8%
|
